US equities
|
MU
$691.44
▲+5.34%
NVDA
$187.82
▲+3.43%
AMD
$445.53
▲+10.17%
SNDK
$824.92
▲+2.29%
SPCX
$134.63
▲+8.91%
TSLA
$360.00
▲+4.75%
AAPL
$343.86
▼-0.09%
MSFT
$532.40
▼-0.66%
MU
$691.44
▲+5.34%
NVDA
$187.82
▲+3.43%
AMD
$445.53
▲+10.17%
SNDK
$824.92
▲+2.29%
SPCX
$134.63
▲+8.91%
TSLA
$360.00
▲+4.75%
AAPL
$343.86
▼-0.09%
MSFT
$532.40
▼-0.66%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Acumen Pharmaceuticals, Inc. - Common Stock
(NQ:
ABOS
)
0.2160
+0.0022 (+1.03%)
Delayed Quote
Updated: 2:48 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acumen Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 29, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 28, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 11, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals's Earnings: A Preview
↗
March 25, 2024
Via
Benzinga
Trading SMID Biotech Stocks In A Volatile Market
↗
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024
↗
May 14, 2024
ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 14, 2024
Via
Benzinga
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 07, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
April 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
↗
March 26, 2024
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
March 26, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
March 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 26, 2024
↗
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
Via
Benzinga
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
March 19, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
March 12, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
March 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
February 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
February 01, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
↗
January 30, 2024
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding.
Via
InvestorPlace
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
↗
January 24, 2024
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population.
Via
InvestorPlace
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
↗
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
↗
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
